Halozyme Therapeutics, Inc. (LON:0J2O)

Market Cap	5.75B
Revenue (ttm)	860.31M
Net Income (ttm)	406.76M
Shares Out	n/a
EPS (ttm)	3.19
PE Ratio	14.14
Forward PE	8.79
Dividend	n/a
Ex-Dividend Date	n/a

Volume	585
Average Volume	905
Open	65.51
Previous Close	65.28
Day's Range	64.11 - 66.08
52-Week Range	42.51 - 79.41
Beta	n/a
RSI	38.59
Earnings Date	Nov 3, 2025

About Halozyme Therapeutics

Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States and internationally. The company’s products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 that facilitates subcutaneous (SC) administration to enhance the disper...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 1998
• Employees: 350
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0J2O

Financial Performance

In 2024, Halozyme Therapeutics's revenue was $1.02 billion, an increase of 22.44% compared to the previous year's $829.25 million. Earnings were $444.09 million, an increase of 57.71%.

Financial numbers in USD